Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06912048 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease

Study acronym: CPB_Atropine
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints revised (9)v5
  2. Secondary endpoints: 8 to 9v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2025 to May 14, 2025
    • Site details revised
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the influence of parasympathetic transmission from the brain to different metabolic organs. This transmission can be blocked with the muscarinic antagonist atropine. Participants will undergo an oral glucose tolerance test combined with a double tracer dilution technique either with atropine infusion or placebo. Healthy individuals and high-risk individuals will be compared to identify possible changes in signaling in high-risk groups. In addition, men and women will be included to take into account possible sex differences.
Trial Details
NCT Number NCT06912048
Lead Sponsor University of Ulm
Conditions
(from sponsor)		 Autonomic Function
Related terms Insulin Resistance
Enrollment 52 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov